Cargando…
Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy model
Micro-dystrophin gene replacement therapies for Duchenne muscular dystrophy (DMD) are currently in clinical trials, but have not been thoroughly investigated for their efficacy on cardiomyopathy progression to heart failure. We previously validated Fiona/dystrophin-utrophin-deficient (dko) mice as a...
Autores principales: | Piepho, Arden B., Lowe, Jeovanna, Cumby, Laurel R., Dorn, Lisa E., Lake, Dana M., Rastogi, Neha, Gertzen, Megan D., Sturgill, Sarah L., Odom, Guy L., Ziolo, Mark T., Accornero, Federica, Chamberlain, Jeffrey S., Rafael-Fortney, Jill A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981810/ https://www.ncbi.nlm.nih.gov/pubmed/36874243 http://dx.doi.org/10.1016/j.omtm.2023.02.001 |
Ejemplares similares
-
Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model
por: Howard, Zachary M., et al.
Publicado: (2021) -
Metabolic Dysfunction and Altered Mitochondrial Dynamics in the Utrophin-Dystrophin Deficient Mouse Model of Duchenne Muscular Dystrophy
por: Pant, Meghna, et al.
Publicado: (2015) -
Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy
por: Howard, Zachary M., et al.
Publicado: (2022) -
Muscle Twitch Kinetics Are Dependent on Muscle Group, Disease State, and Age in Duchenne Muscular Dystrophy Mouse Models
por: Peczkowski, Kyra K., et al.
Publicado: (2020) -
Corrigendum: Muscle Twitch Kinetics Are Dependent on Muscle Group, Disease State, and Age in Duchenne Muscular Dystrophy Mouse Models
por: Peczkowski, Kyra K., et al.
Publicado: (2022)